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Abstract
Objective Benefits of social support (SS) during cancer survivorship are complex. This study examines change in SS over time in
cervical cancer (CXCA) survivors who have completed definitive treatment and how changing SS impacts quality of life (QOL)
and T-helper type 2 (Th2) cytokines.
Methods We conducted a randomized trial in 204 CXCA survivors to test if psychosocial telephone counseling (PTC) could
improve QOL compared to usual care (UC). Although PTC did not target SS, data were collected at baseline, 4 and 9 months
post-enrollment using the Medical Outcomes Survey Social Support scale. Biospecimens were collected to investigate associ-
ations with patient-reported outcomes. Data were analyzed using multivariate linear models and stepwise regression.
Results Participants’ mean age was 43. PTC participants experienced increasing SS compared to UC at 4 months (PTC-UC =
5.1; p = 0.055) and 9 months (PTC-UC = 6.0; p = 0.046). Higher baseline SS and increasing SS were independently associated
with improved QOL at 4 and 9 months after adjusting for patient characteristics (p < 0.05). Differences between study arms were
not statistically significant. Improvements in QOL at 4 months were observed with increases in emotional/informational and
tangible SS. Increasing SS predicted significant longitudinal decreases in IL-4 and IL-13 at 4 months that were larger in the PTC
arm (interactions p = 0.041 and p = 0.057, respectively).
Conclusion Improved SS was significantly associated with improved QOL independent of patient characteristics and study arm.
Decreasing Th2 cytokines with increasing SS and QOL are consistent with a biobehavioral paradigm in which modulation of the
chronic stress response is associated with shifts in immune stance.
Keywords Cancer survivorship . Quality of life . Social support
Introduction
Cervical cancer (CXCA) survivors have among the worst
physical- and mental health-related quality of life (QOL) re-
ported in cancer survivor populations [1–4]. QOL disruptions
persist after definitive therapy and long into survivorship
[5–7]. This has negative implications for long-term survival
in CXCA because of the well-established association between
QOL and cancer survival [8]. One potential target for improv-
ing QOL is social support (SS), broadly defined as emotional,
informational, and instrumental assistance provided by one’s
social network [9, 10]. Longitudinal and cross-sectional studies
have established strong positive associations for SS with phys-
ical and psychosocial aspects of long-term cancer survivorship
[11–17]. In the broader population of cancer survivors, SS has
been associated with decreased cancer-related stress and de-
pressive symptoms [11, 12], positive psychosocial change
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[13], better QOL [14], and lower mortality [15–17]. In CXCA
survivors, higher SS is significantly associated with better
QOL 5–20 years after diagnosis [18, 19].
The longitudinal trajectory for SS in cancer survivors may
be quite different from other QOL domains. In CXCA pa-
tients, QOL is generally below the level of healthy reference
populations at diagnosis [6, 20] but increases significantly
post-treatment [6, 20–23]. While some studies report QOL
equal to general population norms 6 months post-diagnosis
[20, 24], studies of advanced stage CXCA report physical
and mental health components of QOL below the norm
throughout survivorship [6, 25]. In contrast to the increasing
trend for QOL, SS appears to decline over treatment and
follow-up [6, 20, 23]. Ding et al. [23] noted a significant
decrease in social/family well-being (p = 0.025) over 9months
in early stage CXCAwhile Kirchheiner et al. [20] reported that
social functioning in locally advanced CXCA recovered
slightly at 6 months before decreasing over long-term fol-
low-up. Dahiya et al. [22] noted no significant change in so-
cial functioning in stage II–IV CXCA survivors 6 months
post-treatment but longer follow-up was not available.
Survivors treated with radiotherapy reported less opportunity
to share worries with others compared to population-based
controls and decreasing interaction with others over time [6].
Thus, SS appears to decline over survivorship in CXCA.
Sustained improvements in SS post-treatment may positively
impact QOL and overall survival.
A growing body of literature has sought to elucidate the
biologic mechanisms by which improvement in QOL affects
health outcomes among cancer survivors [26]. Chronic stress
may impact tumor growth and progression through activation
of pathways in the sympathetic nervous system and hypotha-
lamic-pituitary-adrenal-axis, influencing inflammatory re-
sponses by immune cells [27]. Potential effects of behavioral
interventions include decreases in T-helper class 2 (Th2) in-
flammatory cytokines, reductions in helper/suppressor (Th1/
Th2) ratios. and higher levels of natural killer cell cytotoxicity
(NKCC) [28]. CXCA survivors randomized to a healing touch
intervention experienced greater decrease in depressive symp-
toms and less decline in NKCC compared to survivors random-
ized to UC [29]. Psychosocial intervention with breast cancer
survivors reduced psychological distress and increased disease-
free and overall survival [30, 31]. The intervention arm had
significantly higher SS and greater immune activity (NKCC)
compared to controls [31]. Higher NKCC and Th1/Th2 ratio,
and decreases in the inflammatory cytokine IL-4 have also been
observed with higher SS [32]. Less is known about how chang-
es in SS are related to changes in such biomarkers.
We previously conducted a randomized controlled trial de-
signed to test the hypothesis that a psychosocial telephone
counseling (PTC) intervention improves QOL [33]. Eligible
patients included CXCA survivors identified through the
California Cancer Registries with stage I-IVA disease who
had completed definitive treatment. Patients were randomized
1:1 to usual care (UC) or weekly PTC. The intervention was
designed to help patients manage chronic stress, improve
health and wellness, and manage sexual side effects of disease
and treatment. Results showed non-significant improvements
at 4- and 9-month follow-up in overall QOL (p = 0.26 and p =
0.13), and significant improvement in depression and gyneco-
logic and cancer-specific concerns among the PTC partici-
pants relative to UC (p < 0.05 for all). Improved QOL was
significantly associated with decreases in Th2 and counter-
regulatory cytokines, supporting a shift in immune stance
and possible reduction in the chronic stress response regard-
less of study arm [26, 27, 34]. Although the PTC intervention
was not designed to modify SS, we collected data on SS as a
supplemental outcome at baseline and follow-up to better un-
derstand the role of SS on changing QOL and stress-related
biomarkers. We report here on longitudinal changes in SS and
associations with changes in QOL and stress-related bio-
markers in CXCA survivors.
Methods
Participants
After approval by the Institutional Review Boards of the
University of California, Irvine and California Cancer
Registries, CXCA survivors were identified from the
California Cancer Registries (Orange, Los Angeles,
Imperial, and San Diego Counties). Eligibility criteria were
(1) stage I to IVA CXCA (locally advanced but without dis-
seminated metastasis), (2) completion of definitive treatment
at least 2 months earlier, and (3) ability to speak and read
English or Spanish. Exclusion criteria were (1) treatment with
biologic response modifiers or prior immunotherapy within
4 weeks of study enrollment, (2) treatment with investigation-
al drugs within 30 days, (3) required corticosteroids, and (4)
immunosuppression. Participants were enrolled in the trial 9–
30 months from diagnosis and randomly assigned to PTC or
UC with stratification by ethnicity. Prior to enrolling, all par-
ticipants provided informed consent.
Measures
Surveys were conducted via mail with follow-up phone calls
as needed. SS was measured using the Medical Outcomes
Survey Social Support (MOS-SS) questionnaire, a 19-item
multidimensional, self-administered survey of SS developed
for patients with chronic conditions [35]. Responses are
ranked on a Likert scale from 1 (none of the time) to 5 (all
of the time), and indicate how often respondents perceive the
availability of a particular source of support. Subdomains
measured include (1) emotional/informational support,
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measuring perception of received empathy, displays of posi-
tive affect, encouragement of emotional expression, and per-
ception of ready sources of advice and guidance; (2) positive
social interaction, measuring perceived availability of others
to engage in enjoyable activities; (3) affection, measuring per-
ceived reception of love and affection; and (4) tangible sup-
port, measuring perceived receipt of material and behavioral
assistance. Scores are calculated by taking the average of all
items and transforming to a standardized score ranging from 0
to 100. This measure has been validated in both English and
Spanish and is reliable and stable over time (Cronbach’s alpha
≥ 0.96 at each of the three time points).
QOL was measured using the Functional Assessment of
Cancer Therapy-Cervical (FACT-Cx). This instrument is a
multidimensional, combined generic and disease-specific
QOL questionnaire that includes the FACT-General (FACT-
G) questionnaire (version 4) consisting of four subscales
(physical, social, emotional, and functional well-being) plus
the cervical cancer-specific additional concerns subscale.
Subdomains are summed to produce the FACT-Cx score
(Cronbach’s α = .92). Additional patient-reported measures
included in the study but not in the present analysis can be
found in Wenzel et al. [33].
Biomarkers
Biospecimens were collected at the participant’s locale in ac-
cordance with verbal and written instructions. Standard phle-
botomy was performed into EDTAVacutainer® tubes. Blood
was transported at ambient temperature from the collection
site to the laboratory where it was processed, typically within
60–180 min. Plasma was collected by centrifugation,
aliquoted and stored at – 80 °C until analyzed. All samples
were tested in duplicate with Milliplex® MAP High
Sensit ivity Human Cytokine Magnetic Bead Kit,
HSCYTMAG-60SK (EMD Millipore, Billerica, MA).
Patient samples from multiple time points were run on a
single plate. Data were collected with MAGPIX®
xPONENT software (Luminex, Austin, TX) and analyzed
with Milliplex® Analyst 5.1 software. Biomarkers analyzed
for this work included Th2 cytokines IL-4, IL-5, and IL-13.
Statistical methods
Comparisons of baseline characteristics between treatment
arms were performed using t tests and univariate analysis of
variance for continuous variables. Chi-square analyses were
used for categorical variables. Primary outcomes of interest
are the MOS-SS standard score and the FACT-Cx measure of
QOL. Changes over time in SS were compared between study
arms using multivariate analysis of variance for repeated mea-
sures. Effect sizes were calculated as the difference between
arms divided by the pooled baseline standard deviation (SD).
Data were adjusted for baseline values. Trends over time were
tested from baseline to 4 and 9 month follow-ups with signif-
icance level p < 0.05.
The contribution of change in SS to change in QOL was
assessed using stepwise general linear models and stepwise
multivariable linear regression with a backward stepping pro-
cedure. Alphas to remove and enter were set at 0.015.
Covariates included in the model were study arm, treatment,
baseline QOL, baseline SS, and SS change (baseline to 4 or
9 month follow-up). Cancer treatment was included as a co-
variate because we have previously shown a significant dif-
ference in change over time in QOL by treatment [34].
Interaction terms were investigated. Change in SS was includ-
ed as either a continuous variable or as a categorical variable
(ΔSS < -10, − 10 < ΔSS < 10, and ΔSS > 10).
Associations between longitudinal changes in SS and cy-
tokine levels were investigated across all subjects using step-
wise multivariate linear models with change in cytokine level
as the dependent variable. Independent variables included age,
baseline cytokine level, study arm, and change in SS from
baseline to follow-up. Interactions were added to test if the
effect of change in SS differed between PTC and UC.
Specimens with variance from ambient transportation and
overtly lipemic samples were excluded. Methods are de-
scribed in detail elsewhere [33].
Results
Study subjects
A total of 204 out of 685 eligible CXCA survivors with phone
contact (30%) were enrolled in the study and randomized to
either PTC (n = 115) or UC (n = 89) (Fig. 1). Subject recruit-
ment and baseline characteristics are described in detail else-
where [23]. Completion rates at 4 and 9-month follow-up
were 74% and 66% in PTC and 93% and 84% in UC.
Survivors were on average 45 years of age at study entry
and 19.4 months from diagnosis (range = 9–30). There were
no significant differences between subjects randomized to
PTC and UC with respect to age, ethnicity, marital status,
income, education, stage, treatment, or prior comorbidities.
Baseline SS and overall QOL (FACT-Cx) were 74.1 (SD =
19.6) and 128.9 (SD = 21.9), respectively, in the PTC arm
compared to 70.3 (SD = 25.0) and 123.7 (SD = 23.7) in the
UC arm. These differences were not statistically significant
(p = 0.28 and p = 0.14, respectively).
Changes over time in social support
Social support increased significantly from baseline to 4-
month follow-up in PTC (p < 0.001) and non-significantly in
UC (p = 0.09) before declining at 9 months in both groups
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(Table 1, Fig. 2a). Differences between PTC and UC were
5.1 at 4 months (effect size = 0.28, p = 0.055) and 6.0 at
9 months (effect size = 0.30, p = 0.046). Significantly, more
PTC participants experienced increasing SS compared to UC
at 4 months (54% vs. 37%, p = 0.016) and 9 months (47% vs.
33%, p = 0.034).
Similar differences between PTC and UCwere observed in
longitudinal change for all subdomains of the MOS-SS scale
(Table 1, Fig. 2b–e). Effect sizes ranged from 0.26 to 0.36 at
4 months and from 0.19 to 0.52 at 9 months. The largest
differences between PTC and UC were for tangible support
(effect size at 4 months = 0.36, p = 0.05; effect size at
9 months = 0.52, p = 0.006).
Changes in social support associated with changes
in QOL
Both baseline SS and change in SS (Table 2) were significant-
ly associated with change in QOL at 4-and 9-month follow-
up, however differences between study arms were not signif-
icant. In the PTC arm, a decrease in SS of 10 points at T2 (0.5
SD) was associated with a decrease in QOL of − 4.3 while an
increase in SS of 10 (0.5 SD) at T2 was associated with an
increase in QOL of + 12.1 (Fig. 3a). In the UC arm, a decrease
in SS of 10 points at T2 was associated with a decrease of −
5.9 and an increase in SS of 10 at T2 was associated with an
increase of + 8.0. The difference between arms was not sig-
nificant (p = 0.46). Similar associations were observed in PTC
and UC arms for changes in SS at 9 months (Fig. 3b; p = 0.47
for difference between arms). After adjustment for SS, the
PTC-UC difference in QOL change was reduced from 2.4 to
1.4 at 4 months and from 3.3 to 1.5 at 9 months (Fig. 3c).
While change in QOL did not differ significantly between
arms, adjustment for SS did reduce the magnitude of observed
change in QOL by approximately 50%, suggesting that SS
may partially mediate changes in QOL.
When all subdomains (emotional/informational, tangible,
affection, and positive interaction) were included separately
as independent variables in stepwise regression models,
emotional/informational (p < 0.001) and tangible SS (p =
0.04) were significant independent predictors of improvement
Table 1 Differences over time for MOS social support in PTC and UC
Differences at 4 months Differences at 9 months
Absolute differences (T2–T1)a Group difference
in change T2–T1
Absolute differences (T3-–T1)a Group difference
in change T3–T1
UC PTC PTC-
UC
Effect sizeb p value UC PTC PTC-
UC
Effect sizeb p value
Social support-all
Total score 1.67 6.76 5.08 0.28 0.055 − 0.14 5.87 6.01 0.30 0.046
Emotional/informational 3.40 8.02 4.61 0.26 0.142 2.18 7.39 5.21 0.26 0.110
Tangible − 1.40 5.02 6.42 0.36 0.048 − 5.09 5.26 10.34 0.52 0.006
Affection 1.13 6.15 5.02 0.28 0.088 − 0.71 3.03 3.74 0.19 0.294
Positive interaction 1.15 7.23 6.09 0.34 0.099 − 0.35 5.92 6.27 0.31 0.121
aDifferences adjusted for baseline value
b Effect size = difference between arms/SD
Fig. 1 CONSORT diagram of ascertainment and recruitment. PTC =
pyschosocial telephone counseling
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in QOL at 4 months (multiple r = 0.56) whereas emotional/
informational (p < 0.001) and positive interaction (p = 0.047)
subdomains were independently associated with improvement
in QOL at 9 months (multiple r = 0.60).
Associations between change in social support
and Th2 cytokines
Increasing SS from baseline to 4 months was significantly
associated with decreasing IL-4 (p = 0.010) and decreasing
IL-13 (p = 0.005) after adjusting for age and baseline cytokine
level in multivariate linear models (Table 3). Furthermore, the
decreases in IL-4 and IL-13 with increasing SS were greater in
the PTC arm than for UC (interaction effects: p = 0.041 and
p = 0.057 for IL-4 and IL-13, respectively). Change in IL-5 at
4 months was not associated with changes in SS, nor were
changes in cytokine levels at 9 months associated with chang-
ing SS (p = 0.59, p = 0.57, and p = 0.08 for change in IL-4, IL-
5, and IL-13, respectively).
Discussion
The present study describes changes in social support over time
in a randomized controlled trial of PTC to improve QOL in
CXCA survivors. Although changing SS was not a focus of
the PTC intervention, SS data were collected as a supplemental
study aim. Our aims in this analysis were to describe longitu-
dinal changes in SS following an intervention designed to im-
prove overall QOL and to investigate associations with changes
in QOL and stress-related biomarkers. Longitudinal trends
showed an increase in SS post-intervention and a decline in
Fig. 2 Longitudinal change in
patient-reported social support.
Psychosocial telephone
counseling (PTC) (solid lines)
and usual care (UC) (dotted lines)
is represented at baseline (T1),
4 months (T2), and 9 months
(T3). Error bars represent SEs. a
MOS total social support standard
scores. b Emotional/
informational social support
subdomain. c Tangible social
support subdomain. d Positive
interaction social support
subdomain. e Affection social
support subdomain
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SS at long-term follow-up in both arms. There was a significant
difference between study arms at the 9-month follow-up (p =
0.046) and a nearly significant difference at 4 months (p =
0.055). The effect size of 0.28–0.30 was small to moderate
and the study was under-powered to detect significance (pow-
er = 54% in post hoc analysis). A decline in overall SS at ex-
tended follow-up has been consistently observed in other stud-
ies [20, 23]. Perhaps the most parsimonious explanation is that
as health improves over time, there is less perceived need for
SS. Alternatively, as noted by Moyer et al. [36], there may be a
discrepancy between the perceptions of patients and their sup-
porters, with supporters believing they are continuing to pro-
vide needed support while providing less support over time.
Thus, the drop off in SS may not necessarily reflect less need
for support from the patient’s view, as suggested by associations
between decreased SS and increased distress and depression at
follow-up reported in the literature [11, 12, 36, 37].
It is noteworthy that the PTC intervention achieved greater
improvement relative to UC in all subdomains of SS, though
statistical significance was only reached for tangible support.
Tangible support includes the perceived availability of help
with aspects of daily life such as transportation, meals and
housework. Effect sizes (0.36 at 4 months and 0.52 at
9 months) reflect a clinically meaningful difference in tangible
support between PTC and UC participants. While tangible
support increased in PTC following the intervention and
remained stable at long-term follow-up, a continuous decrease
was observed in UC, consistent with other studies [20, 23, 36,
37]. Even without a PTC module focusing specifically on SS,
counselors’ use of problem- and emotion-focused coping
strategies may have contributed to improved SS and, more
specifically, to sustained improvement in tangible support. In
the future, sustained efforts via targeted sessions devoted to
SS plus continued contact between the counselor and survivor
through text messaging and/or booster sessions over a long
term might help sustain an increase in all SS domains.
Greater SS at a single time point has been shown to have a
positive effect on QOL in both cross-sectional and longitudi-
nal studies [14, 19, 23, 36, 37]. A notable limitation of prior
studies, however, is the absence of data on the impact of
changes in SS during survivorship on QOL change over time.
In our study, both baseline SS and change in SS were
Table 2 Stepwise linear regression model predicting change in quality of life (FACT-Cx)
Dependent variable Independent variable* Coefficient SE Standard coefficient t p value
Change in FACT-Cx at 4 months (T2–T1)
A. Model with SS Total Constant 30.17 5.39 0.00 5.59 < 0.001
N = 165 FACT-Cx (baseline) − 0.33 0.05 − 0.52 − 6.29 < 0.001
Multiple r = 0.557 Social support (baseline) 0.19 0.06 0.29 3.06 0.003
Δ Social support (T2–T1) 0.35 0.06 0.44 5.72 < 0.001
Study arm (PTC) 1.40 1.91 0.05 0.74 0.462
B. Model with SS Subdomains Constant 29.96 5.45 0.00 5.50 < 0.001
N = 164 FACT-Cx (baseline) − 0.33 0.05 − 0.53 − 6.23 < 0.001
Multiple r = 0.561 Social support (baseline) 0.19 0.06 0.30 3.17 0.002
Δ Tangible support 0.11 0.05 0.16 2.07 0.040
Δ Emotional/informational Support 0.22 0.05 0.36 4.23 < 0.001
Study arm (PTC) 1.42 1.91 0.05 0.74 0.459
Change in FACT-Cx at 9 months (T3–T1)
C. Model with SS Total Constant 36.11 6.29 0.00 5.74 < 0.001
N = 150 FACT-Cx (baseline) − 0.33 0.06 − 0.49 −5.67 < 0.001
Multiple r = 0.581 Chemo-radiation (0 vs 1) − 4.23 2.10 − 0.14 − 2.01 0.046
Social Support (baseline) 0.15 0.06 0.23 2.47 0.015
Δ Social Support (T3–T1) 0.34 0.06 0.44 5.82 < 0.001
Study Arm (PTC) 1.52 2.09 0.05 0.73 0.469
D. Model with SS Subdomains Constant 34.40 6.28 0.00 5.48 < 0.001
N = 150 FACT-Cx (baseline) − 0.32 0.06 − 0.47 − 5.53 < 0.001
Multiple r = 0.596 Chemo-radiation (0 vs 1) − 4.25 2.09 − 0.14 − 2.04 0.043
Social support (baseline) 0.15 0.06 0.22 2.45 0.016
Δ Emotional/informational support 0.24 0.05 0.36 4.45 < 0.001
Δ Positive interaction support 0.87 0.04 0.17 2.16 0.032
Study arm (PTC) 1.68 2.06 0.06 0.81 0.418
*Independent variables included in stepwise model: study arm, treatment, baseline FACT-Cx, baseline social support, Δ social support)
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independently associated with QOL change. A decrease in SS
of 10 points (approximately 0.5 SD) is associated with de-
creases in QOL of 4.3 and 5.9 points for PTC and UC sub-
jects, respectively, while an increase in SS of 10 points is
associated with increases in QOL of 12.1 and 8.0 points for
PTC and UC, independent of baseline SS. Improvements in
QOL with increasing SS were clinically meaningful (effect
size ≥ 0.5 SD) [38, 39], persisted over time, and were reported
by both PTC and UC participants.
Although significantly, more patients in the PTC arm re-
ported improved SS compared to UC, there was no significant
difference between study arms in the effect of improved SS on
Fig. 3 Longitudinal change in QOL (Fact-Cx) with change in SS.
Changes in SS for PTC and UC are categorized as ΔSS < − 10 (dark
gray), − 10 < ΔSS < 10 (pattern) and ΔSS > 10 (black). a Change in
QOL from T1 to T2: trend in QOL change across ΔSS categories is
significant (p < 0.001) after adjusting for baseline values. b Change in
QOL from T1 to T3, trend in QOL change across ΔSS categories is
significant (p < 0.001) after adjusting for baseline values. c PTC-UC
difference in QOL change. Adjustment for SS change reduces the
difference in QOL change between PTC and UC from 2.4 to 1.4 (T2–
T1) and from 3.3 to 1.5 (T3–T1)
Table 3 Change in Th2/counter-regulatory cytokines with change in social support
Dependent variable Independent variable Coefficient SE Standard coefficient F p value
Change in IL-4 (T2–T1) Constant 18.96
(N = 103) Baseline IL-4 − 0.21 0.04 − 0.47 29.99 < 0.001
Multiple r = 0.537 Age − 0.32 0.21 − 0.13 2.40 0.124
Δ Social support (T2–T1) − 0.26 0.10 − 0.23 6.99 0.010
Study arm x ΔSS 0.19 0.09 0.18 4.28 0.041
Change in IL-13 (T2-T1) Constant 1.11
(N = 102) Baseline IL-13 − 0.22 0.04 − 0.51 37.58 < 0.001
Multiple r = 0.576 Δ Social support (T2–T1) − 0.08 0.03 − 0.24 8.40 0.005
Study arm x ΔSS 0.05 0.03 0.16 3.71 0.057
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QOL change. There are several possible explanations for this
finding. First, improvement in SS related to PTC may be
modest because the intervention was not designed to improve
SS, rather focusing on improving QOL through decreasing
stress, managing relationships, and improving health behav-
iors. It is conceivable that contact with study personnel in both
arms might have contributed some support to all cancer sur-
vivors, thus diluting the difference between study arms. It is
also reasonable to hypothesize that among PTC participants,
counseling on stress management, enhanced communication,
and improvement in health and wellness may have included
some discussion about seeking and obtaining SS as a mean-
ingful dialog to bolster PTC success.
A number of studies have suggested that SS may serve as a
mediator or moderator for psychosocial outcomes [40]. In a
study of end stage renal disease, SS was a partial mediator for
the effect of depressive symptoms on QOL [41], and SS par-
tially mediated the relationship between optimism and depres-
sion in women at high risk for breast cancer [42]. SS was not
found to moderate the effect of a nutritional intervention on
psychological functioning in women with breast cancer [43].
In our study, it would be reasonable to ask whether SS might
mediate the effect of PTC on change in QOL. Although the
PTC-UC difference in QOL change is reduced by approximate-
ly 50% after adjusting for change in SS (Fig. 2c), the overall
effect of PTC on change in QOL did not reach statistical sig-
nificance [33]. Even though PTC influences change in SS (p =
0.055 at 4 months), and change in SS clearly impacts change in
QOL (p < 0.001), the requirements for a mediation model [44,
45] are not met because PTC did not have a significant effect on
QOL change, perhaps due to lack of power [33]. Furthermore,
SS does not appear to moderate the effect of PTC on change in
QOL in our study since both study arms experience similar
effects (as evidenced by the non-significant interaction for SS
change by study arm). With post-treatment CXCA survivors in
our study, SS appears to influence QOL independent of the
PTC intervention. Evaluation of the role of SS as mediator
and/or moderator in future studies where the intervention is
specifically designed to improve SS would be of interest.
The beneficial effect of SS on QOL and general health has
been hypothesized to reflect a buffering of the effects of stress
on the neuroendocrine and immune systems [26–29, 34].
Consistent with this hypothesis, Miyazaki et al. [32] also
showed significantly higher NK activity, lower IL-4, and a
shift in the Th1/Th2 balance associated with high SS. Our
results showing that SS is associated with a decrease in the
Th2 cytokines IL-4 (p = 0.010) and IL-13 (p = 0.005) at 4-
month follow-up independent of baseline cytokine level, most
prominently in the PTC arm as supported by the observed
interaction effect, further support the integration of SS into
the biobehavioral paradigm for cancer survivorship.
Limitations of this study include the sample size and lim-
ited power to detect significant differences over time. Subjects
who dropped from the study had significantly lower QOL and
non-significantly lower SS at baseline, particularly in the PTC
arm. These subjects presumably had the most to gain from the
intervention, thus their absence from the analysis may have
reduced effect sizes and limited our ability to detect differ-
ences between study arms. Nevertheless, both study arms im-
proved in SS over time. Contact with study personnel at mul-
tiple time points for completion of questionnaires and blood
draws may have provided some support for cancer survivors
in the UC arm, again reducing the differences between arms.
In summary, we found that increases in SS are strongly
associated with improved QOL over time and that this is true
across all dimensions of QOL (physical, social, emotional,
functional, and additional concerns) after adjusting for differ-
ences in baseline level of SS, regardless of study arm. Although
the intervention in the present study was not designed to im-
prove SS, the strong and durable relationship between SS and
QOL provides reason to believe that an intervention targeted to
improve SS throughout survivorship would potentially yield
even greater improvements in SS, QOL and potentially addi-
tional biobehavioral outcomes in this population.
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